The genomic medicine company initially raised $50m in an offering that enabled WuXi PharmaTech to exit, before its stock rose significantly post-IPO.
US-based genomic healthcare technology developer Syros Pharmaceuticals closed an initial public offering that allowed pharmaceutical company WuXi PharmaTech to exit at $57.5m yesterday.
Syros issued an initial four million shares priced at $12.50 last week before selling an additional 600,000 shares to its underwriters. The company’s stock closed at $18.00 on Nasdaq yesterday afternoon.
Founded in 2011, Syros develops therapeutics medicines that aim to control expression of disease-driving genes by targeting the non-coding region of the genome.
The company…
